Priya Chockalingam

Company: Beam Therapeutics

Job title: Vice President, Head of Clinical Bioanalytics & Translational Sciences

Seminars:

Addressing Key Translational Challenges of Base Editing Technology 1:45 pm

For somatic base editing programs, how can a drug sponsor prove no germline edits have occurred? Detection of on- and off-target genome editing events in the clinical setting Outlining the unique regulatory considerations for clearing an IND with a base editing programRead more

day: Day 2 Track B PM